Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more
Market Cap & Net Worth: Ginkgo Bioworks Holdings (DNA)
Ginkgo Bioworks Holdings (NYSE:DNA) has a market capitalization of $341.10 Million ($341.10 Million) as of March 19, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #13124 globally and #5501 in its home market, demonstrating a 3.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ginkgo Bioworks Holdings's stock price $6.83 by its total outstanding shares 49941878 (49.94 Million).
Ginkgo Bioworks Holdings Market Cap History: 2021 to 2026
Ginkgo Bioworks Holdings's market capitalization history from 2021 to 2026. Data shows change from $16.60 Billion to $341.10 Million (-56.44% CAGR).
Ginkgo Bioworks Holdings Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ginkgo Bioworks Holdings's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.44x
Ginkgo Bioworks Holdings's market cap is 2.44 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $16.60 Billion | $313.84 Million | -$1.83 Billion | 52.90x | N/A |
| 2022 | $3.38 Billion | $477.71 Million | -$2.10 Billion | 7.07x | N/A |
| 2023 | $3.38 Billion | $251.46 Million | -$892.87 Million | 13.43x | N/A |
| 2024 | $490.43 Million | $227.04 Million | -$547.03 Million | 2.16x | N/A |
| 2025 | $415.02 Million | $170.16 Million | -$312.76 Million | 2.44x | N/A |
Competitor Companies of DNA by Market Capitalization
Companies near Ginkgo Bioworks Holdings in the global market cap rankings as of March 19, 2026.
Key companies related to Ginkgo Bioworks Holdings by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Ginkgo Bioworks Holdings Historical Marketcap From 2021 to 2026
Between 2021 and today, Ginkgo Bioworks Holdings's market cap moved from $16.60 Billion to $ 341.10 Million, with a yearly change of -56.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $341.10 Million | -17.81% |
| 2025 | $415.02 Million | -15.38% |
| 2024 | $490.43 Million | -85.47% |
| 2023 | $3.38 Billion | 0.00% |
| 2022 | $3.38 Billion | -79.66% |
| 2021 | $16.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ginkgo Bioworks Holdings was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $341.10 Million USD |
| MoneyControl | $341.10 Million USD |
| MarketWatch | $341.10 Million USD |
| marketcap.company | $341.10 Million USD |
| Reuters | $341.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.